BTIG reiterates Buy on MiniMed Group stock, $25 target on AID growth
#BTIG #MiniMed Group #Buy rating #price target #Automated Insulin Delivery #AID #stock #investment
📌 Key Takeaways
- BTIG maintains a Buy rating on MiniMed Group stock.
- The firm sets a $25 price target for MiniMed Group.
- The positive outlook is driven by growth in Automated Insulin Delivery (AID) systems.
- The reiteration suggests continued confidence in the company's performance.
🏷️ Themes
Stock Analysis, Medical Technology
Entity Intersection Graph
No entity connections available yet for this article.